Logo image of FATE

FATE THERAPEUTICS INC (FATE) Stock Price, Quote, News and Overview

NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD

1.31  +0.07 (+5.65%)

After market: 1.33 +0.02 (+1.53%)

FATE Quote, Performance and Key Statistics

FATE THERAPEUTICS INC

NASDAQ:FATE (5/2/2025, 8:00:02 PM)

After market: 1.33 +0.02 (+1.53%)

1.31

+0.07 (+5.65%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.92
52 Week Low0.66
Market Cap150.13M
Shares114.60M
Float110.37M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07/amc
IPO10-01 2013-10-01


FATE short term performance overview.The bars show the price performance of FATE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 60 80

FATE long term performance overview.The bars show the price performance of FATE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of FATE is 1.31 USD. In the past month the price increased by 92.65%. In the past year, price decreased by -67.73%.

FATE THERAPEUTICS INC / FATE Daily stock chart

FATE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About FATE

Company Profile

FATE logo image Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Company Info

FATE THERAPEUTICS INC

12278 Scripps Summit Drive

San Diego CALIFORNIA 92121 US

CEO: J. Scott Wolchko

Employees: 181

Company Website: https://fatetherapeutics.com/

Investor Relations: https://ir.fatetherapeutics.com/

Phone: 18588751803

FATE THERAPEUTICS INC / FATE FAQ

What is the stock price of FATE THERAPEUTICS INC today?

The current stock price of FATE is 1.31 USD. The price increased by 5.65% in the last trading session.


What is the ticker symbol for FATE THERAPEUTICS INC stock?

The exchange symbol of FATE THERAPEUTICS INC is FATE and it is listed on the Nasdaq exchange.


On which exchange is FATE stock listed?

FATE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FATE THERAPEUTICS INC stock?

19 analysts have analysed FATE and the average price target is 6.52 USD. This implies a price increase of 397.46% is expected in the next year compared to the current price of 1.31. Check the FATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FATE THERAPEUTICS INC worth?

FATE THERAPEUTICS INC (FATE) has a market capitalization of 150.13M USD. This makes FATE a Micro Cap stock.


How many employees does FATE THERAPEUTICS INC have?

FATE THERAPEUTICS INC (FATE) currently has 181 employees.


What are the support and resistance levels for FATE THERAPEUTICS INC (FATE) stock?

FATE THERAPEUTICS INC (FATE) has a support level at 1.31 and a resistance level at 1.38. Check the full technical report for a detailed analysis of FATE support and resistance levels.


Is FATE THERAPEUTICS INC (FATE) expected to grow?

The Revenue of FATE THERAPEUTICS INC (FATE) is expected to decline by -66.7% in the next year. Check the estimates tab for more information on the FATE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy FATE THERAPEUTICS INC (FATE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FATE THERAPEUTICS INC (FATE) stock pay dividends?

FATE does not pay a dividend.


When does FATE THERAPEUTICS INC (FATE) report earnings?

FATE THERAPEUTICS INC (FATE) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of FATE THERAPEUTICS INC (FATE)?

FATE THERAPEUTICS INC (FATE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).


What is the Short Interest ratio of FATE THERAPEUTICS INC (FATE) stock?

The outstanding short interest for FATE THERAPEUTICS INC (FATE) is 14.12% of its float. Check the ownership tab for more information on the FATE short interest.


FATE Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to FATE. When comparing the yearly performance of all stocks, FATE is a bad performer in the overall market: 86.85% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

FATE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to FATE. While FATE has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FATE Financial Highlights

Over the last trailing twelve months FATE reported a non-GAAP Earnings per Share(EPS) of -1.64.


Industry RankSector Rank
PM (TTM) N/A
ROA -42.27%
ROE -58.44%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%2.22%
Sales Q2Q%10.98%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)-78.54%

FATE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to FATE. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 5.51% and a revenue growth -66.7% for FATE


Ownership
Inst Owners88.96%
Ins Owners2%
Short Float %14.12%
Short Ratio5.96
Analysts
Analysts74.74
Price Target6.52 (397.71%)
EPS Next Y5.51%
Revenue Next Year-66.7%